Funding for this research was provided by:
Gunnar Nilssons Cancerstiftelse (170516)
Received: 23 March 2018
Accepted: 11 July 2018
First Online: 6 August 2018
Ethics approval and consent to participate
: Ethical approval was obtained from the ethics committee at Lund University (original study file no. 2009/658 , the following amendments are also approved: 2010/383 (expansion of sites for SCAN-B, including Blekinge County Hospital, Central Hospital Växjö and Hallands Hospital Halmstad), 2012/58 (updated patient information for SCAN-B v3), 2015/277 (updated patient information for SCAN-B v4), 2015/522 (The SCAN-B Resilience study), 2017/875 (The SCAN-B Resilience study in Helsingborg) and 2017/88 ( The one-year follow up of SCAN-B Resilience).). “ The committee sees no ethical problems to approve the planned study with the condition that samples sent abroad should be returned to a Biobank in Sweden after conducting analyses and that the consent is signed by the person who provided the information”. All patients must give written informed consent to participate in the study. Participation in the SCAN-B Resilience study is voluntary, and the participants have the right at any time, without any reason, to cancel their attendance.
: Not applicable.
: The authors declare that they have no competing interests. The study has received governmental funding and has thus been peer-reviewed by the funding body VINNOVA.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.